|Institution||National Institute for Cellular Biotechnology, Dublin City University|
Dr Fiona O'Neill has been a member of the pancreatic cancer research group in the NICB, since 2014. Her PhD thesis was entitled "An examination of the pharmacology of HER2 inhibitor responses in cellular models of breast cancer."
As a member of the pancreatic cancer research group, she is responsible for the generation of patient derived xenograft and primary cell culture of the tumour material.
The National Institute for Cellular Biotechnology (NICB) is a multidisciplinary centre of research in fundamental and applied cellular biotechnology, molecular cell biology, ocular disease and biological chemistry. The centre as a whole is geared towards the use of cutting edge techniques to gain a deeper understanding of human cancer and how it can be better detected, treated and monitored. The centre boasts access to a wide array of human cancer cell lines as well as a state of the art "omics" and mass spectrometry core facility.
Patient management (wg4)